Orgenesis Inc (NASDAQ:ORGS) announced a collaboration with Johns Hopkins University to utilize its point-of-care platform to develop and supply gene therapies and technologies.
The company’s POCare cell therapy platform is designed to advance the development of Advanced Therapy Medicinal Products — medicines based on genes, tissues or cells — through collaborations and in-licensing with other companies.
CEO Vered Caplan is confident in the pedigree and resources of the Baltimore research university.